Payment overview · 2025
General Payments
$1,265.40
67 reported records · 26 companies
Healthcare provider profile · identity verified
Khaleel Deeb, MD
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, OH · NPI 1053387761
Verified facts
What the public records show
CMS Open Payments records show Khaleel Deeb, MD received $1,265.40 in general payments during 2025 across 67 reported records.
Exact Sciences Corporation accounted for 10.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Ingrezza, Invega Sustenna, Jardiance, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 564 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 664 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 669 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 664 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 669 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $129.03 | 10.2% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $112.63 | 8.9% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.25 | 8.1% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $101.54 | 8.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.88 | 7.5% | 5 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $69.18 | 5.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.95 | 5.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.67 | 4.2% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.10 | 3.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.53 | 3.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.05 | 3.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $43.97 | 3.5% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $38.81 | 3.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.19 | 2.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.83 | 2.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.73 | 2.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.45 | 2.1% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.83 | 2.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.82 | 2.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.77 | 2.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.37 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.41 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.05 | 1.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.62 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.87 | 1.1% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$13.87 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,222.90 | 66 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $116.00 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $79.66 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $77.97 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $71.78 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $69.18 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.95 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $62.72 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.25 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.19 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $49.10 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.05 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $45.01 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $43.97 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $36.25 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $34.83 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $34.83 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.45 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 669 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 564 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 664 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 170 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
85 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
564 | 61 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
664 | 74 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
669 | 78 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
170 | 36 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
185 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
664 | 74 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
105 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
199 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
669 | 78 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1590 | 280 |
| Amlodipine Besylate | Amlodipine Besylate | 1135 | 232 |
| Metformin Hcl | Metformin Hcl | 820 | 153 |
| Lisinopril | Lisinopril | 745 | 151 |
| Gabapentin | Gabapentin | 731 | 126 |
| Eliquis | Apixaban | 669 | 78 |
| Jardiance | Empagliflozin | 664 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 648 | 123 |
| Trazodone Hcl | Trazodone Hcl | 570 | 94 |
| Farxiga | Dapagliflozin Propanediol | 564 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 556 | 135 |
| Metoprolol Succinate | Metoprolol Succinate | 539 | 115 |
| Tamsulosin Hcl | Tamsulosin Hcl | 535 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 530 | 106 |
| Losartan Potassium | Losartan Potassium | 508 | 102 |
| Mirtazapine | Mirtazapine | 470 | 90 |
| Omeprazole | Omeprazole | 467 | 93 |
| Sertraline Hcl | Sertraline Hcl | 466 | 62 |
| Carvedilol | Carvedilol | 465 | 94 |
| Escitalopram Oxalate | Escitalopram Oxalate | 455 | 77 |
| Furosemide | Furosemide | 436 | 90 |
| Quetiapine Fumarate | Quetiapine Fumarate | 393 | 44 |
| Ezetimibe | Ezetimibe | 389 | 78 |
| Divalproex Sodium | Divalproex Sodium | 388 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 382 | 65 |
| Potassium Chloride | Potassium Chloride | 337 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 264 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 68 |
| Buspirone Hcl | Buspirone Hcl | 239 | 34 |
| Allopurinol | Allopurinol | 229 | 41 |
| Olanzapine | Olanzapine | 213 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 211 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 208 | 34 |
| Baclofen | Baclofen | 199 | 23 |
| Ozempic | Semaglutide | 199 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 198 | 64 |
| Lactulose | Lactulose | 198 | 24 |
| Risperidone | Risperidone | 189 | 26 |
| Aripiprazole | Aripiprazole | 188 | 24 |
| Xarelto | Rivaroxaban | 185 | 21 |
| Benztropine Mesylate | Benztropine Mesylate | 184 | 22 |
| Haloperidol | Haloperidol | 182 | 33 |
| Finasteride | Finasteride | 174 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 170 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 169 | 47 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 156 | suppressed |
| Levetiracetam | Levetiracetam | 153 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 149 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 149 | 44 |
| Memantine Hcl | Memantine Hcl | 144 | 21 |
| Tramadol Hcl | Tramadol Hcl | 134 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 132 | 19 |
| Donepezil Hcl | Donepezil Hcl | 128 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 128 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 127 | 31 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 125 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 121 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 21 |
| Famotidine | Famotidine | 114 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 114 | 50 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 111 | 22 |
| Tradjenta | Linagliptin | 111 | 11 |
| Chlorthalidone | Chlorthalidone | 110 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 110 | 42 |
| Meloxicam | Meloxicam | 108 | 26 |
| Telmisartan | Telmisartan | 108 | 25 |
| Entresto | Sacubitril/Valsartan | 105 | 11 |
| Midodrine Hcl | Midodrine Hcl | 102 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 101 | 27 |
| Topiramate | Topiramate | 100 | 18 |
| Vraylar | Cariprazine Hcl | 100 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 93 | 25 |
| Oxcarbazepine | Oxcarbazepine | 91 | suppressed |
| Simvastatin | Simvastatin | 91 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 89 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 89 | suppressed |
| Torsemide | Torsemide | 87 | 25 |
| Myrbetriq | Mirabegron | 85 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 84 | 19 |
| Dapagliflozin | Dapagliflozin Propanediol | 83 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 16 |
| Alendronate Sodium | Alendronate Sodium | 82 | 19 |
| Atenolol | Atenolol | 82 | 18 |
| Clonazepam | Clonazepam | 80 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 23 |
| Trulicity | Dulaglutide | 79 | 15 |
| Bupropion Xl | Bupropion Hcl | 78 | 12 |
| Calcium Acetate | Calcium Acetate | 75 | suppressed |
| Insulin Lispro | Insulin Lispro | 75 | 17 |
| Latanoprost | Latanoprost | 74 | 11 |
| Metformin Hcl Er | Metformin Hcl | 73 | 17 |
| Spironolactone | Spironolactone | 72 | 21 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 72 | suppressed |
| Gemtesa | Vibegron | 70 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 70 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 21 |
| Lovastatin | Lovastatin | 67 | 16 |
| Linzess | Linaclotide | 66 | 13 |
| Prednisone | Prednisone | 65 | 18 |
| Alprazolam | Alprazolam | 64 | 17 |
| Ibuprofen | Ibuprofen | 63 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 28 |
| Warfarin Sodium | Warfarin Sodium | 62 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 15 |
| Vancomycin Hcl | Vancomycin Hcl | 60 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 59 | 13 |
| Kapspargo Sprinkle | Metoprolol Succinate | 59 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Colchicine | Colchicine | 53 | 15 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | 11 |
| Xifaxan | Rifaximin | 51 | suppressed |
| Nitroglycerin | Nitroglycerin | 50 | 22 |
| Ranolazine Er | Ranolazine | 50 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | 19 |
| Azithromycin | Azithromycin | 48 | 41 |
| Calcitriol | Calcitriol | 48 | 11 |
| Haloperidol Decanoate | Haloperidol Decanoate | 47 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 46 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 45 | suppressed |
| Lorazepam | Lorazepam | 45 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Nystatin | Nystatin | 43 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | 16 |
| Naproxen | Naproxen | 41 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 41 | suppressed |
| Anastrozole | Anastrozole | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 13 |
| Olanzapine Odt | Olanzapine | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 29 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 26 |
| Budesonide | Budesonide | 38 | 11 |
| Cephalexin | Cephalexin | 38 | 26 |
| Naltrexone Hcl | Naltrexone Hcl | 38 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Ketoconazole | Ketoconazole | 35 | 11 |
| Invega Sustenna | Paliperidone Palmitate | 34 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 34 | suppressed |
| Acarbose | Acarbose | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 26 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Nyamyc | Nystatin | 33 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 32 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 13 |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 25 |
| Sodium Chloride | 0.9 % Sodium Chloride | 32 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Ingrezza | Valbenazine Tosylate | 31 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 30 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 30 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Zonisamide | Zonisamide | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 24 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Cimetidine | Cimetidine | 26 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 25 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Clozapine | Clozapine | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 13 |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 21 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | 11 |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Valproic Acid | Valproic Acid | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Levocarnitine | Levocarnitine | 17 | suppressed |
| Neupro | Rotigotine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Glucagon Emergency Kit | Glucagon | 16 | suppressed |
| Loxapine | Loxapine Succinate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Paliperidone Er | Paliperidone | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Galantamine Er | Galantamine Hbr | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Mitigare | Colchicine | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Tetrabenazine | Tetrabenazine | 12 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,265.40 · 67 records | Exact Sciences Corporation | AFREZZA, AIRSUPRA, AREXVY, AUSTEDO XR, CAMZYOS, CAPVAXIVE, COBENFY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, GARDASIL 9, GEMTESA, HETLIOZ, INGREZZA, INVEGA SUSTENNA, JARDIANCE, KRYSTEXXA, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, ONPATTRO, OTEZLA, PURIFIED CORTROPHIN GEL, RECORLEV, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, Veozah, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error